They say it’s ‘unstoppable’ – How I made 43,509%

Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.

Jeffrey Jonas Biography and Net Worth

Director of Karuna Therapeutics

Dr. Jeff Jonas applies his 25+ years of well-recognized expertise in neuroscience, drug development, and pipeline expansion to his role as Chief Executive Officer at ABio-X. He most recently served as Chief Innovation Officer (CInO) and chair of Sage’s Science & Technology Forum of the Board. Prior to that he served as CEO at Sage from 2013 – 2020, providing his creative, innovative thinking to building one of the industry’s leading brain health product pipelines. Dr. Jonas is well-known for encouraging a pursuit of new opportunities by taking smart risks and challenging conventional wisdom. His approach is shaped by a career that encompasses one-on-one patient care, rapid advancement through corporate structures, academic accomplishments, and entrepreneurial endeavors. Before joining the Sage team, Dr. Jonas served as President of the Regenerative Medicine Division of Shire Plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. He is a member of the board for Generation Bio and Karuna Therapeutics. He has published more than 190 scientific papers and articles, chapters, abstracts and books, and has received numerous awards.

Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.

What is Jeffrey M. Jonas' net worth?: The estimated net worth of Jeffrey M. Jonas is at least $326,531.70 as of September 1st, 2023. Dr. Jonas owns 990 shares of Karuna Therapeutics stock worth more than $326,532 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Jonas may own. Learn More about Jeffrey M. Jonas' net worth.
How do I contact Jeffrey M. Jonas?: The corporate mailing address for Dr. Jonas and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Jeffrey M. Jonas' contact information.
Has Jeffrey M. Jonas been buying or selling shares of Karuna Therapeutics?: Jeffrey M. Jonas has not been actively trading shares of Karuna Therapeutics during the last ninety days. Most recently, Jeffrey M. Jonas sold 13,809 shares of the business's stock in a transaction on Friday, September 1st. The shares were sold at an average price of $187.93, for a transaction totalling $2,595,125.37. Following the completion of the sale, the director now directly owns 990 shares of the company's stock, valued at $186,050.70. Learn More on Jeffrey M. Jonas' trading history.
Who are Karuna Therapeutics' active insiders?: Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.
Are insiders buying or selling shares of Karuna Therapeutics?: In the last twelve months, insiders at the sold shares 12 times. They sold a total of 89,119 shares worth more than $20,412,131.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.
Information on this page was last updated on 3/8/2024.

Jeffrey M. Jonas Insider Trading History at Karuna Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/1/2023	Sell	13,809	$187.93	$2,595,125.37	990
8/1/2023	Sell	13,810	$195.81	$2,704,136.10	990

Jeffrey M. Jonas Buying and Selling Activity at Karuna Therapeutics

Karuna Therapeutics Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $329.83

$329.83

50 Day Range

MA: $325.66

$313.97

$329.83

2 Week Range

Now: $329.83

$158.38

$329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

They say it’s ‘unstoppable’ – How I made 43,509%

From Investing Daily | Ad

Click here now for the full story.